Abstract. Retinoic acid (RA) plays a critical role in cell growth and tissue development. RA is also a regulating factor of pituitary function. RA is synthesized from retinoids through oxidation processes. The oxidation of retinal to RA is catalyzed by the retinaldehyde dehydrogenases (RALDHs), including RALDH1, RALDH2 and RALDH3. Recently, we demonstrated that RALDH1 is expressed in the anterior pituitary glands of adult male rats. However, the expression of RALDH1 in the female pituitary gland and the regulation of RALDH1 expression have not been determined. Therefore, we examined the expression of RALDH1 mRNA in the pituitary glands of adult female rats. By in situ hybridization with digoxigenin-labeled cRNA probes and quantitative real-time PCR analysis, we found that the expression level of RALDH1 was significantly lower in estrus as compared to proestrus, metestrus and diestrus. RALDH1 mRNA levels increased after ovariectomy and decreased remarkably after a 1-week treatment with 17β-estradiol implants. Estradiol (0.01-100 µg per rat) dose-dependently decreased the expression of RALDH1 in the pituitary glands after 24 hours of subcutaneous administration. These results clearly show that RALDH1 mRNA expression is suppressed by estrogen. We speculate that the generation of RA is regulated by estrogen and that RA plays a role in the estrus cycle through paracrine and/or autocrine mechanisms in the anterior pituitary gland of female rats.
RETINOIC acid (RA) is an essential factor for not only normal embryogenesis but also maintenance of multiple tissues in vertebrates. RA is generated intracellularly through the oxidation of retinol in target cells. RA is converted from retinal by retinaldehyde dehydrogenases (RALDHs), RALDH1, RALDH2 and RALDH3. These enzymes are expressed in different areas of developmental and adult tissues. These different expression patterns, which vary by location and developmental stage, play specific roles in various tissues [1, 2] .
We previously reported that RALDH2 and RALDH3, but not RALDH1, are expressed in the embryonic anterior pituitary gland of the rat [3] . We recently also reported that RALDH1 mRNA, but not RALDH2 or RALDH3 mRNA, is expressed in the anterior pituitary gland of adult rats [4] . We speculated that RA may play a role as an autocrine and/or paracrine signaling molecule in the anterior pituitary gland. However, the mechanism that regulates the gene expression of these enzymes in the pituitary gland is not known. We previously identified RALDH1 mRNA expression in the lactotrophs (prolactin-producing cells in the adult pituitary gland) of male rats [4] . The functions of lactotrophs, including cell proliferation and hormone synthesis and release, are controlled by estrogen in the female animals [5] [6] [7] . We were interested in determining whether RALDH1 mRNA expression is affected by estrogen. In the present study, we examined the expres-sion of RALDH1 in female pituitary glands and the effect of estrogen on the expression of RALDH1.
Materials and Methods

Animals
Adult female and male Wistar rats (9-12 weeks) were purchased from Japan SLC, Inc. (Shizuoka, Japan). Animals were maintained on a 12-h light/dark cycle with illumination from 0700 h to 1900 h. Rats were given access to conventional food and water ad libitum. Room temperature was controlled at around 22°C. All animals were treated in accordance with the Guidelines for Animal Experimentation of Jichi Medical University, which is based on the Guide for the Care and Use of Laboratory Animals of the National Academy of Sciences, USA.
The estrous cycle stage was monitored by daily vaginal smears that were collected for one week. Female rat pituitary glands were obtained from 0900 h to 1000 h.
Female rats were ovariectomized under ether anesthesia. Ovariectomized rats were divided into two groups for use in two different experiments. In the first experiment, the rats received subcutaneous implants of a silastic tube (inner diameter 2.0 mm, outer diameter 3.0 mm, length 20 mm; Kaneka Medix Co., Osaka, Japan) containing 17β-estradiol (Sigma Chemical Co., St. Louis, MO, USA) at the time of ovariectomy. The rats were killed one week after the operation or the estradiol tube implantation. Rats used in the second experiment received a subcutaneous injection of 17β-estradiol in corn oil (Wako Pure Chemicals, Osaka, Japan) vehicle three days after ovariectomy. These animals were killed 24 h after the 17β-estradiol injection. The control rats received only corn oil.
Tissue preparation
For in situ hybridization, female rats were deeply anesthetized with an intraperitoneal injection of sodium pentobarbital (25 mg/kg body weight, Nembutal, Dainippon Pharmaceutical, Osaka, Japan). Rats were then perfused with 4% formaldehyde in 0.05 M cacodylate buffer (CB; pH 7.4) for 5 min through the left ventricle, and then immersed in the same fixative for 20-24 h at 4°C. The tissues were immersed for more than 2 days in CB containing 30% sucrose at 4°C, embedded in Tissue Tek compound (Sakura Finetechnical Co., Tokyo, Japan) and frozen rapidly. Frozen frontal sections of 8-µm thickness were obtained by using a cryostat (CM3000; Leica Inc., Buffalo, NY, USA) and mounted on glass slides.
In situ hybridization
In situ hybridization was performed according to our previous report [4] . Rat RALDH1 DNA fragments (GenBank accession # BC061526; 935-1485) were amplified from rat anterior pituitary gland cDNA by polymerase chain reaction (PCR) with forward (5'-CTA CCA TCA AGG CCA ATG CT-3') and reverse (5'-CAC CCA GTT CTC GTC CAT TT-3') primers. Amplified cDNA fragments were ligated into the pGEM-T easy vector (Promega, Madison, WI, USA) and cloned. Gene-specific antisense or sense digoxigenin (DIG)-labeled cRNA probes were made using the Roche DIG RNA labeling kit (Roche Diagnostics GmbH, Penzberg, Germany).
DIG-labeled cRNA probe hybridization was performed in solution containing 50% formamide, 10% dextran sulfate (Wako Pure Chemical Industries, Ltd., Osaka, Japan), 3 × SSC, 120 mM phosphate buffer (pH 7.4), 1 × Denhardt solution (Nacalai Tesque Inc., Kyoto, Japan), 125 µg/ml tRNA (Invitrogen, Carlsbad, CA, USA), and 100 µg/ml sonicated sperm DNA (Invitrogen) at 60°C for 16-18 h. Visualization of each type of mRNA was performed with alkaline phosphatase-conjugated anti-DIG antibody (Roche Diagnostics GmbH) using 4-nitroblue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl phosphate (Roche Diagnostics GmbH). A control experiment was performed, and no specific signal was detected in sections processed with DIG-labeled sense RNA probe.
Quantification of RALDH1 mRNA levels by real-time PCR
Quantitative real-time PCR was performed according to our previous report [4] . Total RNA was extracted from the pituitary gland by using Trizol reagent (Invitrogen) according to the manufacturer's instructions and was incubated with RNase-free DNase I (1 U per tube, Promega) to remove genomic DNA contamination. After the inactivation of DNase I by heating, cDNA was synthesized by the Superscript III reverse transcription kit using oligo-(dT) 20 primer (Invitrogen). Quantitative real-time PCR (ABI PRISM 7900HT; Applied Biosystems, Foster City, CA., USA) was performed using gene-specific primers and SYBR Premix Ex Taq (TAKARA BIO INC., Otsu, Japan) containing SYBR Green I. The following primers were used to amplify cDNA fragments of RALDH1 (GenBank accession # BC061526; 1324-1465): forward (5'-ATG GTC TAG CAG CAG GAG T-3') and reverse (5'-CCA GAC ATC TTG AAT CCA CCG AA-3'). To standardize, we also quantified beta-actin (NM_031144; 337-442) by using forward (5'-TGG CAC CAC ACT TTC TAC AAT GAG C-3') and reverse (5'-GGG TCA TCT TTT CAC GGT TGG-3') primers.
Statistical analysis
The data are presented as the mean ± SE for 4 to 8 animals in each group. Statistical analysis was performed using Fisher's protected least significant difference. P-values less than 0.05 were considered statistically significant.
Results
Expression of RALDH1 mRNA in the adult female pituitary glands RALDH1 mRNA was detected in both male and female adult rat pituitary glands by in situ hybridization with a DIG-labeled antisense cRNA probe (Fig. 1a-f) . RALDH1 mRNA signals in each estrus cycle were weaker than that of the male pituitary gland. The number of RALDH1 mRNA-expressing cells in the estrus stage was less than in the other stages (Fig. 1c-f) .
RALDH1 mRNA levels in the male and female pituitary glands were quantified by real-time PCR. As expected from the results of in situ hybridization, the relative concentration of RALDH1 mRNA in the female pituitary gland was lower than that in the male pituitary gland (Fig. 1g) . In female pituitary glands, the RALDH1 mRNA level was significantly lower at estrus than at proestrus, metestrus or diestrus.
Suppressed expression of RALDH1 mRNA by estrogen RALDH1 mRNA was strongly expressed in the ovariectomized female rats (Fig. 2a and b) ; however, the RALDH1 mRNA signals decreased after 1 week of treatment with 17β-estradiol implants ( Fig. 2c and d) . The expression level of RALDH1 in the pituitary glands of ovariectomized rats, with or without estradiol In the pituitary glands of adult male rats, RALDH1 mRNA was detected in the pars distalis (PD) (a, b). In the female pituitary gland, RALDH1 mRNA expression was lower at estrus (c, d) than at diestrus (e, f). The relative concentration of RALDH1 mRNA in the female pituitary glands was lower than the relative concentration in male pituitary glands (g). In female pituitary glands, the RALDH1 mRNA level was significantly lower at estrus (E) than at proestrus (P), metestrus (M) and diestrus (D treatment, was assessed by quantitative PCR. The RALDH1 mRNA level was significantly decreased in the pituitary glands of the ovariectomized rats that received estradiol treatment (Fig. 2e) . The levels of RALDH1 mRNA expression 24 h after a single subcutaneous injection of various doses of 17β-estradiol are shown in Fig. 3 . The RALDH1 mRNA expression in response to 0.01, 0.1, 1, 10, and 100 µg of 17β-estradiol was suppressed by 13%, 38%, 53%, 64% and 67%, respectively, as compared to the level in control rats that received vehicle only. Thus, estradiol produced a dose-dependent decrease in RALDH1 mRNA expression in the pituitary glands. A time-course analysis of the estradiol effect revealed that the RALDH1 mRNA expression was decreased immediately after 17β-estradiol injection (10 µg per rat, 1 h), with the lowest level detected 6 h after injection (Fig. 3b) . 
Discussion
We previously reported that RALDH1 mRNA is expressed in the anterior pituitary gland of adult male rats [4] . RALDH1 mRNA was expressed in a portion of the prolactin-producing cells (lactotrophs), marginal layer cells that line the hypophysial cleft and folliculostellate cells, in male rats. We suggested that RA is generated by RALDH1 in the adult anterior pituitary gland and may act locally on pituitary cells. However, the expression pattern of RALDH1 in the pituitary gland of female rats is not determined yet. In the present study, we demonstrated that RALDH1 mRNA is expressed in the pituitary glands of adult female rats and that RALDH1 mRNA expression is strongly suppressed by estrogen.
RALDH1 mRNA expression in the female pituitary glands was weaker than that in the male pituitary glands (Fig. 1) . The expression level of RALDH1 mRNA in the estrus stage was lower than the levels in the other stages. These results suggest that RALDH1 mRNA expression is inhibited by estrogen. To clarify the suppressive effect of estrogen on the expression of RALDH1 mRNA, we performed ovariectomies and administered 17β-estradiol. Ovariectomy increased the expression of RALDH1. However, estradiol treatment for 1 week significantly decreased the expression of RALDH1 (Fig. 2) . These results indicate that the depletion of endogenous estrogen induced RALDH1 expression, while exogenous estradiol treatment greatly suppressed RALDH1 expression. In the uterus of rats, Li and colleagues [8] demonstrated that RALDH1 mRNA expression was highest in diestrus and decreased to 10% of the diestrus level in estrus. Moreover, administration of 17β-estradiol (10 µg per rat) to the ovariectomized rats decreased the expression of RALDH1 to 30% of the level in ovariectomized rats when examined 4 h after administration [8] . In another study, estrogen caused a downregulation of the expression of RALDH1 mRNA in the uterine glandular epithelium of mouse between 4 h and 24 h after injection [9] . In the present study, we also demonstrated that RALDH1 expression in the pituitary gland is immediately suppressed by estrogen in a concentration-dependent manner. These results suggest that the expression level of RALDH1 mRNA is regulated by estrogen. However, the molecular mechanism for the downregulation of RALDH1 by estrogen is currently unknown. The estrogen-response element in the rat RALDH1
gene has yet to be identified. The confirmation of direct suppression will require further work.
RA is a regulator of growth hormone (GH)-producing cells (somatotrophs). The RA-responsive element is upstream of Pit-1, a pituitary-specific transacting factor for the prolactin and GH genes [10, 11] . RA induces Pit-1 mRNA transcription [10] and activates GH gene transcription [12] . In addition, RA acts synergistically with corticosteroid to increase GH-releasing hormone receptor mRNA expression [13] . Moreover, RA acts on non-hormone-producing cells among pituitary cells and induces GH-producing cell differentiation in vitro [14] . On the other hand, it was reported that RA also regulates prolactin secretion. Treatment with acitretin, all-trans retinoic acid, caused a persistent reduction of prolactin levels in humans [15] . RA induced the transcription of the dopamine D2 receptor (D2R) gene in cultured rat pituitary cells, and this effect was due to the presence of a functional RAresponse element in the rat D2R promoter [16] . Dopamine potently inhibited prolactin secretion from the anterior pituitary gland via D2R [17] . This finding suggests that D2R induced by RA suppresses the secretion of prolactin from the pituitary gland. We recently reported that RALDH1 mRNA was expressed in the lactotrophs [4] . In the present study, we found that the expression of RALDH1 mRNA is inhibited by estrogen. We speculate that RA is generated by RALDH1, which is regulated by estrogen, and that RA may play a role as a paracrine-and/or autocrine-signaling molecule in the lactotrophs in the estrus cycle of female rats. Additional studies are needed to further elucidate the physiological function of RA in the pituitary gland.
